Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AstraZeneca (NYSE: AZN) today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week (DDW) meeting in Orlando, Florida.
Help employers find you! Check out all the jobs and post your resume.
